Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

• URL: http://arxiv.org/abs/2608.11444v2
• Date: Mon, 17 Aug 2026 20:10:15 GMT
• Title: Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling
• Abstract summary: We substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data.<n>The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity.
• Score: 2.323664982546693
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

Related papers

• Investigating the Impact of Histopathological Foundation Models on Regressive Prediction of Homologous Recombination Deficiency [52.50039435394964]
  We systematically evaluate foundation models for regression-based tasks.<n>We extract patch-level features from whole slide images (WSI) using five state-of-the-art foundation models.<n>Models are trained to predict continuous HRD scores based on these extracted features across breast, endometrial, and lung cancer cohorts.
  arXiv  Detail & Related papers  (2026-01-29T14:06:50Z)
• Integrating Single-Cell Foundation Models with Graph Neural Networks for Drug Response Prediction [3.544038341047844]
  In this study, we investigate whether incorporating the pretrained foundation model scGPT can enhance the performance of existing drug response prediction frameworks.<n> scGPT not only outperforms previous approaches but also exhibits greater training stability, highlighting the value of leveraging scGPT-derived knowledge.
  arXiv  Detail & Related papers  (2025-04-19T17:35:54Z)
• VECT-GAN: A variationally encoded generative model for overcoming data scarcity in pharmaceutical science [32.92218213317144]
  Existing datasets are often small and noisy, limiting their utility.<n>We develop a generative model specifically designed for augmenting small, noisy datasets.<n>We make our method, including VECT-GAN pre-trained on ChEMBL available as a pip package.
  arXiv  Detail & Related papers  (2025-01-15T18:23:33Z)
• MedDiffusion: Boosting Health Risk Prediction via Diffusion-based Data Augmentation [58.93221876843639]
  This paper introduces a novel, end-to-end diffusion-based risk prediction model, named MedDiffusion. It enhances risk prediction performance by creating synthetic patient data during training to enlarge sample space. It discerns hidden relationships between patient visits using a step-wise attention mechanism, enabling the model to automatically retain the most vital information for generating high-quality data.
  arXiv  Detail & Related papers  (2023-10-04T01:36:30Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Targeted-BEHRT: Deep learning for observational causal inference on longitudinal electronic health records [1.3192560874022086]
  We investigate causal modelling of an RCT-established null causal association: the effect of antihypertensive use on incident cancer risk. We develop a dataset for our observational study and a Transformer-based model, Targeted BEHRT coupled with doubly robust estimation. We find that our model provides more accurate estimates of RR compared to benchmarks for risk ratio estimation on high-dimensional EHR.
  arXiv  Detail & Related papers  (2022-02-07T20:05:05Z)
• Bootstrapping Your Own Positive Sample: Contrastive Learning With Electronic Health Record Data [62.29031007761901]
  This paper proposes a novel contrastive regularized clinical classification model. We introduce two unique positive sampling strategies specifically tailored for EHR data. Our framework yields highly competitive experimental results in predicting the mortality risk on real-world COVID-19 EHR data.
  arXiv  Detail & Related papers  (2021-04-07T06:02:04Z)
• Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response [49.86828302591469]
  In this paper, we apply transfer learning to the prediction of anti-cancer drug response. We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset. The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures.
  arXiv  Detail & Related papers  (2020-05-13T20:29:48Z)
• A Systematic Approach to Featurization for Cancer Drug Sensitivity Predictions with Deep Learning [49.86828302591469]
  We train >35,000 neural network models, sweeping over common featurization techniques. We found the RNA-seq to be highly redundant and informative even with subsets larger than 128 features.
  arXiv  Detail & Related papers  (2020-04-30T20:42:17Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.